Improvement of dyslipidemia in patients switching from stavudine to tenofovir:: preliminary results

被引：47

作者：

Domingo, P ^{[1
]}

Labarga, P

Palacios, R

Guerrero, MF

Terrón, JA

Elías, MJP

Santos, J

Camps, MIR

Llibre, JM

Moreno, S

机构：

[1] Hosp Santa Creu & Sant Pau, E-08025 Barcelona, Spain

[2] Hosp San Millan, Logrono, Spain

[3] Hosp Univ Virgen Victoria, Malaga, Spain

[4] Fdn Jimenez Diaz, E-28040 Madrid, Spain

[5] Hosp Jerez, Cadiz, Spain

[6] Hosp Ramon & Cajal, Madrid, Spain

[7] Hosp Gen Valle Hebron, Barcelona, Spain

[8] Hosp Calella, Barcelona, Spain

来源：

AIDS | 2004年 / 18卷 / 10期

关键词：

D O I：

10.1097/01.aids.0000131343.53419.04

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In a prospective, multicentre, switch study to identify the most frequently occurring nucleoside reverse transcriptase inhibitor (NRTI)-associated toxicities that cause NRTI withdrawal in virologically suppressed HIV-infected patients, among those who underwent stavudine substitution by tenofovir, 271 had hypertriglyceridemia and 193 had hypercholesterolemia. After 12 weeks of switching from stavudine to tenofovir, triglyceride and cholesterol levels showed significant decreases, which suggests that such a switch may reverse, at least partly, stavudine-associated dyslipidaemia.

引用

页码：1475 / 1478

页数：4

共 15 条

[1] Tenofovir: A nucleotide analog for the management of human immunodeficiency virus infection [J].